Actualités

Ironwood gains FDA approval to expand Linzess use to children aged two to five years with functional constipation.

ABBV's Decnupaz wins FDA approval for BPDCN, adding its first blood cancer ADC and a new option for an ultra-rare aggressive malignancy.

Hims & Hers is acquiring Australian telehealth platform Eucalyptus as part of its international expansion plan while using $350 million in convertible senior notes.

Over the last 7 days, the United States market has risen by 1.3%, and over the past year, it has climbed an impressive 28%, with earnings forecasted to grow by 17% annually. In this thriving environment, identifying stocks that are trading below their intrinsic value can offer potential opportunities for investors seeking to capitalize on undervalued assets.

Johnson & Johnson seems to have perfected the art of the biotech deal. Rather than spending billions on acquisitions, it has built much of its pharma empire through partnerships that capture huge upside for bargain prices. A biotech partnership is a bit like an open relationship: Your partner can always fall in love with someone else.

The U.S. Food and Drug Administration (FDA) has approved pivekimab sunirine-pvzy (sold under the brand name Decnupaz), a highly targeted therapy for adults dealing with an ultra-rare and aggressive form of blood cancer.

The United States market has shown robust performance with a 2.5% increase over the last week and a remarkable 26% rise in the past year, while earnings are projected to grow by 17% annually. In this thriving environment, identifying stocks that may be trading below their estimated value can offer compelling opportunities for investors seeking to capitalize on potential growth at attractive prices.

ABBV's oncology revenues dip 3% in Q1 as Imbruvica sales slide, though Venclexta, Elahere and Epkinly post solid gains.

AbbVie Inc. (NYSE:ABBV) ranks among the best retirement stocks to buy now. Piper Sandler increased its price target for AbbVie Inc. (NYSE:ABBV) to $298 from $294 on May 14, retaining an Overweight rating on the company’s shares. The firm mentioned AbbVie’s extensive inflammatory bowel disease pipeline as a major source of investor interest. AbbVie Inc. […]

The United States market has shown robust performance, climbing 1.2% in the last week and 29% over the past year, with earnings projected to grow by 17% annually. In such an environment, identifying stocks that are trading below their intrinsic value can present opportunities for investors seeking potential growth at a reasonable price.

Five high-yield names spanning pharmaceuticals, consumer staples, energy, and ETFs offer income investors compelling yields and durable businesses for a ten-year hold.

Most investors buy Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) because the fund’s reputation tells them they are buying diversification. SCHD has 105 holdings, screens hard on dividend quality, and charges 0.06%. The retiree who built an income sleeve around SCHD usually has not read the holdings list. Read the list and the diversification story bends: ... SCHD’s Dividend Quality Filter Now Concentrates 42 Percent of Your Money in Just Ten Stocks

The United States market has shown robust performance, climbing 1.2% in the last week and rising 29% over the past year, with earnings projected to grow by 17% annually in the coming years. In such a thriving environment, identifying stocks that are trading below their intrinsic value can present attractive opportunities for investors seeking potential long-term gains.

Over the last 7 days, the United States market has risen by 1.1%, contributing to an impressive 29% climb over the past year, with earnings forecasted to grow by 17% annually. In such a robust environment, identifying stocks that may be trading below their estimated value can offer potential opportunities for investors seeking to capitalize on market growth while considering intrinsic value.

Johnson & Johnson (NYSE:JNJ) and AbbVie (NYSE:ABBV) both posted Q1 2026 results that beat revenue expectations and prompted raised full-year guidance. JNJ leaned on a diversified pharma plus MedTech engine. AbbVie leaned almost entirely on immunology. Both face biosimilar headwinds, yet each chose a different way to outgrow them. TREMFYA and Cardiovascular Carry JNJ. Skyrizi ... Two Paths to Growth: Johnson & Johnson vs AbbVie

The United States market has experienced a notable uptick, rising 1.1% over the last week and achieving a 29% increase over the past year, with earnings projected to grow by 17% annually in the coming years. In this context of robust growth, identifying stocks that are potentially trading below their estimated fair value can offer investors opportunities to capitalize on undervalued assets with promising prospects.

These healthcare giants have been top dividend stocks for years, and both could be intriguing options to consider right now.

These stocks are built for the long haul. And they pay great dividends.

AbbVie received a positive opinion from the European Medicines Agency's CHMP for Boey for glabellar lines and MAVIRET for acute hepatitis C infection, supporting potential approvals in Europe. The company plans to share new oncology data at the upcoming ASCO Annual Meeting and recently reported strong clinical updates in inflammatory bowel disease therapies. These developments highlight AbbVie's expanding presence in aesthetics, antivirals and immunology alongside upcoming oncology...

Holding a high-yield dividend portfolio in a taxable account at the 24% federal bracket means writing the IRS a $14,400 check every year on $60,000 of income that should have been yours. It repeats annually, forever, on the same dollars you already earned. This series exists because most readers know what a Roth IRA is ... The Dividend Stocks That Generate $60,000 Tax-Free Inside a Roth (And What They Cost You in a Taxable Account)

AbbVie Inc. (NYSE:ABBV) is one of the best low risk stocks to buy in 2026. On May 5, AbbVie presented 18 abstracts at the 2026 Digestive Disease Week Annual Meeting, highlighting new real-world and clinical trial data for its IBD therapies, Skyrizi (risankizumab) and Rinvoq (upadacitinib). The findings demonstrate the long-term efficacy, safety, and durability […]

When investors take a risk-off attitude, stocks with attractive, growing dividends are often their safe-haven option.

The United States market has experienced a flat week but has shown significant growth over the past year with a 27% increase, and earnings are anticipated to grow by 17% annually. In this context, identifying stocks that may be trading below their estimated value can offer opportunities for investors seeking to capitalize on potential future gains.

Replacing a real paycheck with dividends is the cleanest version of financial independence. The income target here is $65,000 per year, roughly the US median individual wage, and the question is whether a $650,000 portfolio can actually produce it. The honest answer up front: only by reaching past pure blue chips into higher-yield categories. Here ... The Dividend Stocks That Can Replace a $65,000 Income and What They’ll Cost You

This big pharma stock checks off a lot of boxes.

In the last week, the United States market has stayed flat, yet it is up 27% over the past year with earnings expected to grow by 17% per annum in the coming years. In this context, identifying stocks that may be undervalued by the market involves looking for companies whose intrinsic value might not be fully reflected in their current share prices despite these positive growth trends.

GSK shares slide after Q1 despite earnings and sales beats, as investors weigh slowing legacy drug sales against strong Specialty Medicines growth.

In the last week, the United States market has stayed flat, yet it is up 27% over the past year with earnings forecasted to grow by 17% annually. In such an environment, identifying potentially undervalued stocks like Fifth Third Bancorp can offer investors opportunities for growth at a reasonable price.

The Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) has built its reputation on paying reliable, growing quarterly distributions to income investors, and the latest data confirms why holders trust the fund. SCHD paid $0.2569 per share on March 30, 2026, continuing an uninterrupted quarterly schedule that stretches back to 2011. For retirees and dividend-growth investors weighing ... Why retirees are banking on SCHD’s 15-year unbroken dividend streak

AbbVie Inc. (NYSE:ABBV) is one of Louis Navellier’s top long-term stock picks. On May 14, Piper Sandler reiterated an Overweight rating on AbbVie (NYSE: ABBV), buoyed by the company’s inflammatory bowel disease (IBD) pipeline. The research firm also raised its price target to $298 from $294, as management moves forward with Skyrizi in combination with […]